+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for 392 polymorphisms in 141 pharmacogenes



Screening for 392 polymorphisms in 141 pharmacogenes



Biomedical Reports 2(4): 463-476



Pharmacogenomics is the study of the association between inter-individual genetic differences and drug responses. Researches in pharmacogenomics have been performed in compliance with the use of several genotyping technologies. In this study, a total of 392 single-nucleotide polymorphisms (SNPs) located in 141 pharmacogenes, including 21 phase I, 13 phase II, 18 transporter and 5 modifier genes, were selected and genotyped in 150 subjects using the GoldenGate assay or the SNaPshot technique. These variants were in Hardy-Weinberg equilibrium (HWE) (P>0.05), except for 22 SNPs. Genotyping of the 392 SNPs revealed that the minor allele frequencies of 47 SNPs were <0.05, 105 SNPs were monomorphic and 22 variants were not in HWE. Also, based on previous studies, we predicted the association between the polymorphisms of certain pharmacogenes, such as cytochrome P450 2D6, cytochrome P450 2C9, vitamin K epoxide reductase complex, subunit 1, cytochrome P450 2C19, human leukocyte antigen, class I, B and thiopurine S-methyltransferase, and drug efficacy. In conclusion, our study demonstrated the allele distribution of SNPs in 141 pharmacogenes as determined by high-throughput screening. Our results may be helpful in developing personalized medicines by using pharmacogene polymorphisms.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670671

Download citation: RISBibTeXText

PMID: 24944790

DOI: 10.3892/br.2014.272


Related references

Association of pharmacogenes polymorphisms with toxicities and GvHD after HLA-identical sibling bone marrow transplantation. Blood 102(11): 241a-242a, November 16, 2003

Evidence for extensive pleiotropy among pharmacogenes. Pharmacogenomics 17(8): 853-866, 2017

Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clinical Pharmacology and Therapeutics 100(4): 380-388, 2017

Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver. Clinical Pharmacology and Therapeutics 98(2): 205-215, 2015

Combining heterogenous data for prediction of disease related and pharmacogenes. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing: 328-339, 2014

Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clinical Pharmacology and Therapeutics 100(2): 160-169, 2017

Targeted Next-Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes. Clinical Pharmacology and Therapeutics 101(3): 396-405, 2016

Ethnic variability in the allelic distribution of pharmacogenes between Korean and other populations. Pharmacogenetics and Genomics 22(12): 829-836, 2013

Gene-environment interactions of selected pharmacogenes in arterial hypertension. Expert Review of Clinical Pharmacology 5(6): 677-686, 2013

Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenetics and Genomics 18(6): 545-549, 2008

Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health. Pharmacogenomics 17(5): 499-505, 2016

Improving the prediction of pharmacogenes using text-derived drug-gene relationships. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing: 305-314, 2013

Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenetics and Genomics 23(12): 666-674, 2014

Making data on essential pharmacogenes available for every patient everywhere: the Medicine Safety Code initiative. Pharmacogenomics 14(13): 1529-1531, 2014

Harnessing Knowledge on Very Important Pharmacogenes CYP2C9 and CYP2C19 Variation for Precision Medicine in Resource-Limited Global Conflict Zones. Omics 20(10): 604-609, 2017